20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)
Public ClinicalTrials.gov record NCT01568229. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Study identification
- NCT ID
- NCT01568229
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 111 participants
Conditions and interventions
Conditions
Interventions
- AMG 747 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2012
- Primary completion
- May 31, 2013
- Completion
- Jul 31, 2013
- Last update posted
- Sep 30, 2014
2012 – 2013
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Little Rock | Arkansas | 72211 | — |
| Research Site | Springdale | Arkansas | 72764 | — |
| Research Site | Long Beach | California | 90813 | — |
| Research Site | Oakland | California | 94612 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Hialeah | Florida | 33018 | — |
| Research Site | Kissimmee | Florida | 34741 | — |
| Research Site | Atlanta | Georgia | 30328 | — |
| Research Site | Rockville | Maryland | 20850 | — |
| Research Site | Flowood | Mississippi | 39232 | — |
| Research Site | Princeton | New Jersey | 08540 | — |
| Research Site | Buffalo | New York | 14215 | — |
| Research Site | New York | New York | 10027 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Scranton | Pennsylvania | 18503 | — |
| Research Site | Memphis | Tennessee | 38119 | — |
| Research Site | Dallas | Texas | 75230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01568229, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 30, 2014 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01568229 live on ClinicalTrials.gov.